The University of Chicago Header Logo

Connection

Mark Kozloff to Azetidines

Back to Details
This is a "connection" page, showing publications Mark Kozloff has written about Azetidines.
Mark Kozloff
Connection Strength
0.041
Azetidines
  1. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019 06; 20(6):849-861.
    View in: PubMed
    Score: 0.041
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.